These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22330916)

  • 1. Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility.
    Melikian GL; Rhee SY; Taylor J; Fessel WJ; Kaufman D; Towner W; Troia-Cancio PV; Zolopa A; Robbins GK; Kagan R; Israelski D; Shafer RW
    Antimicrob Agents Chemother; 2012 May; 56(5):2305-13. PubMed ID: 22330916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.
    Parikh UM; Bacheler L; Koontz D; Mellors JW
    J Virol; 2006 May; 80(10):4971-7. PubMed ID: 16641288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.
    Ross L; Parkin N; Chappey C; Fisher R; Clair MS; Bates M; Tisdale M; Lanier ER
    AIDS; 2004 Aug; 18(12):1691-6. PubMed ID: 15280780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
    Sluis-Cremer N; Sheen CW; Zelina S; Torres PS; Parikh UM; Mellors JW
    Antimicrob Agents Chemother; 2007 Jan; 51(1):48-53. PubMed ID: 17088490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
    Llibre JM; Bonjoch A; Iribarren J; Galindo MJ; Negredo E; Domingo P; Pérez-Alvarez N; Martinez-Picado J; Schapiro J; Clotet B;
    HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.
    Li Z; Terry B; Olds W; Protack T; Deminie C; Minassian B; Nowicka-Sans B; Sun Y; Dicker I; Hwang C; Lataillade M; Hanna GJ; Krystal M
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5500-8. PubMed ID: 23979732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
    Barnas D; Koontz D; Bazmi H; Bixby C; Jemsek J; Mellors JW
    Antivir Ther; 2010; 15(3):437-41. PubMed ID: 20516563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
    Geleziunas R; Gallagher K; Zhang H; Bacheler L; Garber S; Wu JT; Shi G; Otto MJ; Schinazi RF; Erickson-Viitanen S
    Antivir Chem Chemother; 2003 Jan; 14(1):49-59. PubMed ID: 12790516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
    Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
    PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tenofovir DF in rescue regimens].
    López Bernaldo de Quirós JC
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():25-30. PubMed ID: 19195435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular basis of the association of H208Y and thymidine analogue resistance mutations M41L, L210W and T215Y in the HIV-1 reverse transcriptase of treated patients.
    Betancor G; Nevot M; Mendieta J; Gómez-Puertas P; Martínez MA; Menéndez-Arias L
    Antiviral Res; 2014 Jun; 106():42-52. PubMed ID: 24667336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.
    Røge BT; Katzenstein TL; Obel N; Nielsen H; Kirk O; Pedersen C; Mathiesen L; Lundgren J; Gerstoft J
    Antivir Ther; 2003 Apr; 8(2):173-82. PubMed ID: 12741630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase.
    Parikh UM; Zelina S; Sluis-Cremer N; Mellors JW
    AIDS; 2007 Jul; 21(11):1405-14. PubMed ID: 17589186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.
    Margot NA; Isaacson E; McGowan I; Cheng A; Miller MD
    J Acquir Immune Defic Syndr; 2003 May; 33(1):15-21. PubMed ID: 12792350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).
    Ross L; Elion R; Lanier R; Dejesus E; Cohen C; Redfield RR; Gathe JC; Hsu RK; Yau L; Paulsen D; Ha B;
    AIDS Res Hum Retroviruses; 2009 Jul; 25(7):665-72. PubMed ID: 19563238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
    Santoro MM; Sabin C; Forbici F; Bansi L; Dunn D; Fearnhill E; Boumis E; Nicastri E; Antinori A; Palamara G; Callegaro A; Francisci D; Zoncada A; Maggiolo F; Zazzi M; Perno CF; Ceccherini-Silberstein F; Mussini C
    HIV Med; 2013 Oct; 14(9):571-7. PubMed ID: 23668660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.
    Miller MD; Margot NA; Lamy PD; Fuller MD; Anton KE; Mulato AS; Cherrington JM
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):450-8. PubMed ID: 11511821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
    Stephan C; Dauer B; Khaykin P; Stuermer M; Gute P; Klauke S; Staszewski S
    Curr HIV Res; 2009 May; 7(3):320-6. PubMed ID: 19442129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance-associated mutations after initial antiretroviral treatment failure in a large cohort of patients infected with HIV-1 subtype CRF01_AE.
    Praparattanapan J; Kotarathitithum W; Chaiwarith R; Nuntachit N; Sirisanthana T; Supparatpinyo K
    Curr HIV Res; 2012 Dec; 10(8):647-52. PubMed ID: 23061604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.